Show Summary Details
Page of

Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial 

Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial
Chapter:
Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial
Author(s):

Robert J. Claycomb

DOI:
10.1093/med/9780199377527.003.0048
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 September 2019

This chapter provides a summary of a landmark study in vascular neurology. How does dabigatran compare to adjusted-dose warfarin for risk reduction of stroke in patients with atrial fibrillation? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. This study demonstrated that dabigatran 110 mg and 150 mg are not inferior to adjusted-dose warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.